



DEPARTMENT OF HEALTH AND HUMAN SERVICES

Public Health Service

Center for Drug Evaluation and Research
Office of Regulatory Policy
Division of Information Disclosure Policy
5600 Fishers Lane, HFD-13
Rockville, Maryland 20857

August 24, 2005

In Response Refer to File: F05-8455

ProCon.Org
ATTN: Jeffrey Yablan
100 Wilshire Blvd., 3rd Floor
Santa Monica, CA 90401

Dear Mr. Yablan,

This is in response to your letter of 6/24/05, in which you requested adverse events associated with the use of Marinol. Your request was received in the Center for Drug Evaluation and Research on 6/28/05.

Please find the enclosed data which summarizes reports of events to the above mentioned drug(s). This data contains only reports of adverse events which have been entered into the computerized filing system maintained by the Office of Drug Safety. This AERS report may include duplicate reports (e.g., more than one report for the same adverse event).

Charges of \$74.00 (Search \$19.00, Review \$, Reproduction \$, Computer time \$55.00) will be included in a monthly invoice. **DO NOT SEND ANY PAYMENT UNTIL YOU RECEIVE AN INVOICE.**

If there are any problems with this response, please notify us in writing of your specific problem(s). Please reference the above file number.

This concludes the response from the Center for Drug Evaluation and Research.

Sincerely,

Harold D. Stepper

Paralegal Specialist
Office of Regulatory Policy
Division of Information Disclosure Policy, HFD-13

Adverse Event Reporting System (AERS)

**Freedom Of Information (FOI) Report
Selections for: DRONABINOL**

MARINOL

From: 01-NOV-1997 To: Present

Disclaimer: The information contained in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of adverse drug reactions.

**FDA - Adverse Event Reporting System (AERS)
Freedom Of Information (FOI) Report**

Date: 03/27/98	ISR Number: 3060679-6	Report Type: Expedited (15-Day)	Company Report#: 18651-008	Age:	Gender: Female	I/FU: 1
Outcome: Life-Threatening	PT: Condition Aggravated Convulsion	Report Source: Health Professional	Product: Marinol (Dronabinol)	Role: PS	Manufacturer:	Duration: 3 WK
				Route: ORAL	Dose: 10 MG, BID, PO	
Date: 04/28/98	ISR Number: 3072102-6	Report Type: Direct	Company Report#:	Age: 68 YR	Gender: Male	I/FU: 1
Outcome: Hospitalization - Initial or Prolonged	PT: Embolism	Report Source:	Product: Megace Marinol	Role: PS SS	Manufacturer:	Duration:
				Route:	Dose: 800 MG BID QD 2.5 MG BID QD	
Date: 04/29/98	ISR Number: 3073328-8	Report Type: Direct	Company Report#:	Age: 68 YR	Gender: Male	I/FU: 1
Outcome: Hospitalization - Initial or Prolonged	PT: Embolism Prothrombin Time Prolonged	Report Source: Other	Product: Megace Marinol	Role: PS SS	Manufacturer:	Duration:
				Route: ORAL ORAL	Dose: 800 MG BID QD 2.5MG BID QD	
Date: 09/16/98	ISR Number: 3240006-1	Report Type: Periodic	Company Report#: 18651-007	Age:	Gender: Female	I/FU: 1
Outcome: Other	PT: Blood Pressure Increased Rebound Hypertension	Report Source: Health Professional	Product: Marinol (Dronabinol) Capsules	Role: PS	Manufacturer: Roxane Laboratories	Duration:
				Route:	Dose:	
Date: 05/06/99	ISR Number: 3255101-0	Report Type: Direct	Company Report#:	Age: 46 YR	Gender: Male	I/FU: 1
Outcome: Death	PT: Gastrointestinal Haemorrhage Hepatic Cirrhosis Portal Hypertension Varices Oesophageal	Report Source:	Product: Marinol (Dronabinol)/Placebo ; Roxane	Role: PS	Manufacturer:	Duration:
				Route: ORAL	Dose: 2.5MG PO TID/OMG POTES	
Date: 07/27/99	ISR Number: 3325507-X	Report Type: Periodic	Company Report#: 18651-009	Age: 90 YR	Gender: Female	I/FU: 1
Outcome: Other	PT: Hypotonia	Report Source: Consumer	Product: Marinol (Dronabinol) Capsules, 5 Mg-Roxane	Role:	Manufacturer:	Duration:
				Route:	Dose:	

**FDA - Adverse Event Reporting System (AERS)
Freedom Of Information (FOI) Report**

<u>Date:</u>	<u>ISR Number:</u>	<u>Report Type:</u>	<u>Company Report#:</u>	<u>Age:</u>	<u>Gender:</u>	<u>I/FU:</u>		
07/27/99	3325512-3	Periodic	18651-010	64 YR	Female	I		
<u>Outcome</u> Other	<u>PT</u> Hallucination	<u>Report Source</u> Consumer	<u>Product</u> Marinol (Dronabinol) Capsules, 5 Mg-Roxane Laboratories, Inc.	<u>Role</u> PS	<u>Manufacturer</u> Roxane Laboratories, Inc.	<u>Route</u> ORAL	<u>Dose</u> 5 MG QD PO	<u>Duration</u>
			Prilosec Amor Thyroid Tablets Courmadin Prednisone Potassium Reglan Megestrol Zolof Heart Medication	C C C C C C C C		ORAL	5MG PO HS	
07/27/99	3325517-2	Periodic	18651-011	61 YR	Female	I		
<u>Outcome</u> Other	<u>PT</u> Dyspnoea	<u>Report Source</u> Consumer	<u>Product</u> Marinol (Dronabinol) Capsules, 2.5mg-Roxane Laboratories, Inc.	<u>Role</u> PS	<u>Manufacturer</u> Roxane Laboratories, Inc.	<u>Route</u> ORAL	<u>Dose</u> 2.5MG BID PO	<u>Duration</u>
			Percocet	C		ORAL	2.5MG BID PO	
07/27/99	3325526-3	Periodic	18651-012			I		
<u>Outcome</u> Other	<u>PT</u> Psychotic Disorder	<u>Report Source</u> Consumer	<u>Product</u> Marinol (Dronabinol) Capsules Roxane Laboratories, Inc.	<u>Role</u> PS	<u>Manufacturer</u> Roxane Laboratories, Inc.	<u>Route</u>	<u>Dose</u>	<u>Duration</u>
08/05/99	3322255-7	Direct		61 YR	Male	I		
<u>Outcome</u> Hospitalization - Initial or Prolonged	<u>PT</u> Dyspnoea Oral Intake Reduced Pleural Effusion	<u>Report Source</u>	<u>Product</u> Megace 800mg Po Daily Marinol 2.5mg Po Bid	<u>Role</u> PS SS	<u>Manufacturer</u>	<u>Route</u> ORAL	<u>Dose</u> 800MG PO DAILY	<u>Duration</u>

**FDA - Adverse Event Reporting System (AERS)
Freedom Of Information (FOI) Report**

<u>Date:</u>	<u>ISR Number:</u>	<u>Report Type:</u>	<u>Expedited (15-Day) Company Report#:</u>	<u>Product</u>	<u>Report Source</u>	<u>Role</u>	<u>Manufacturer</u>	<u>Route</u>	<u>Dose</u>	<u>Duration</u>	<u>Gender:</u>	<u>Age:</u>	<u>I/FU:</u>
08/27/99	3336534-0	Periodic	10077584	Taxol Inj (Paclitaxel)	Health Professional	PS		INTRAVENOUS	284 MG 1/1 DAY IV		Male		I
		Abdominal Pain		Carboplat Inj (Carboplatin)	Health Professional	SS		INTRAVENOUS	120 MG 1/1 DAY IV				
		Dehydration		Decadron (Dexamethasone)	Health Professional	SS			20 MG				
		Diarrhoea		Marinol (Tetrahydrocannabinol)	Health Professional	SS							
		Dysphagia		Lopressor	Health Professional	C							
		Fluid Overload		Monopril	Health Professional	C							
		Mental Impairment		A.S.A.	Health Professional	C							
		Nausea		Duragesic	Health Professional	C							
		Pain		Nph	Health Professional	C							
		Vomiting		Reglan	Health Professional	C							
				Humibid L.A.	Health Professional	C							
				Compazine	Health Professional	C							
10/26/99	3384276-8	Periodic	9941785	Viagra Tablets	Consumer	PS					Male		I
		Headache		Marinol	Consumer	SS							
07/07/00	3528170-8	Periodic	18651-013	Marinol	Consumer	PS	Unimed Inc		1.5 MG DAILY		Female		I
		Amnesia		Valium 5-10mg Daily	Consumer	C			10 MG DAILY				
		Hypotension			Consumer				DAILY 2ND MONTH	1 MONTH			MON
07/07/00	3528175-7	Periodic	18651-016	Bactrim Ds	Health Professional	PS	Unimed Inc	ORAL	5MG, TID, PO		Female		I
		Drug Ineffective		Zerit	Health Professional	C							
				Viramune	Health Professional	C							
				Prilosec	Health Professional	C							
				Lorazepam	Health Professional	C							
				Lipitor	Health Professional	C							
				Glucotrol	Health Professional	C							

**FDA - Adverse Event Reporting System (AERS)
Freedom Of Information (FOI) Report**

<u>Date:</u>	<u>ISRN Number:</u>	<u>Report Type:</u>	<u>Periodic</u>	<u>Company Report#:</u>	<u>18651-017</u>	<u>Age:</u>	<u>31 YR</u>	<u>Gender:</u>	<u>Male</u>	<u>I/F/U:</u>	<u>1</u>
<u>Outcome</u> Other	<u>PT</u> Anorectal Disorder Constipation Diarrhoea Hyperhidrosis Migraine Nausea Vomiting	<u>Report Source</u> Consumer Health Professional Other	<u>Product</u> Marinol Oxycontin Benefix (Factor 1x Anticoagulant Factor)	<u>Role</u> PS SS C	<u>Manufacturer</u> Unimed Inc	<u>Route</u>	<u>Dose</u> 5MG, FOR 2, Q 4-8 HRS. PM 1 OR 2 Q4-6 HRS.PM	<u>Duration</u>			
<u>Date:</u>	<u>ISRN Number:</u>	<u>Report Type:</u>	<u>Expedited (15-Day)</u>	<u>Company Report#:</u>	<u>200416</u>	<u>Age:</u>	<u>55 YR</u>	<u>Gender:</u>	<u>Female</u>	<u>I/F/U:</u>	<u>1</u>
<u>Outcome</u> Hospitalization - Initial or Prolonged	<u>PT</u> Blister Dermatitis Skin Ulcer	<u>Report Source</u> Foreign Health Professional Company Representative	<u>Product</u> Ms Contin Marinol (Dronabinol) Musaril (Tetrazepam) Melleril (Thioridazine)	<u>Role</u> PS SS C C	<u>Manufacturer</u> Purdue Frederick Co	<u>Route</u> ORAL	<u>Dose</u> 800 MG QD PO	<u>Duration</u>			
<u>Date:</u>	<u>ISRN Number:</u>	<u>Report Type:</u>	<u>Direct</u>	<u>Company Report#:</u>		<u>Age:</u>	<u>45 YR</u>	<u>Gender:</u>	<u>Male</u>	<u>I/F/U:</u>	<u>1</u>
<u>Outcome</u> Life-Threatening Required Intervention to Prevent Permanent Impairment/Damage	<u>PT</u> Murder	<u>Report Source</u>	<u>Product</u> Dronabinol Fluconazole Morphine Lorazepam Ondansetron Promethazine Prochlorperazine Lorazepam Haloperidol	<u>Role</u> PS C C C C C C C C	<u>Manufacturer</u>	<u>Route</u>	<u>Dose</u>	<u>Duration</u>			
<u>Date:</u>	<u>ISRN Number:</u>	<u>Report Type:</u>	<u>Expedited (15-Day)</u>	<u>Company Report#:</u>	<u>DRON00200006511</u>	<u>Age:</u>	<u>82 YR</u>	<u>Gender:</u>	<u>Male</u>	<u>I/F/U:</u>	<u>1</u>
<u>Outcome</u> Hospitalization - Initial or Prolonged	<u>PT</u> Asthma Blood Pressure Systolic Increased Chest Pain Gastritis Hypersomnia Medication Error Oedema Tremor Vomiting	<u>Report Source</u> Study Health Professional	<u>Product</u> Marinol Exelon (Rivastigmine Tartrate) Zolof (Sertraline Hydrochloride)	<u>Role</u> PS SS C	<u>Manufacturer</u> Unimed Inc	<u>Route</u> ORAL ORAL	<u>Dose</u> 5 MG BID PO 4.5 MG BID PO	<u>Duration</u>			
<u>Date:</u>	<u>ISRN Number:</u>	<u>Report Type:</u>	<u>Expedited (15-Day)</u>	<u>Company Report#:</u>	<u>DRON00200006572</u>	<u>Age:</u>	<u>79 YR</u>	<u>Gender:</u>	<u>Male</u>	<u>I/F/U:</u>	<u>1</u>
<u>Outcome</u> Death	<u>PT</u> Cardiac Failure Congestive	<u>Report Source</u> Study Health Professional	<u>Product</u> Marinol Toprol XL (Metoprolol)	<u>Role</u> PS	<u>Manufacturer</u> Unimed Inc	<u>Route</u> ORAL	<u>Dose</u> 5 MG BID PO	<u>Duration</u>			

**FDA - Adverse Event Reporting System (AERS)
Freedom Of Information (FOI) Report**

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening Hospitalization - Initial or Prolonged	Chest Pain Myocardial Infarction Myocardial Ischaemia Nausea Vomiting	Study Health Professional	Marinol	PS	Unimed Inc	ORAL	5 MG BID PO, 2.5 MG BID PO	
			Norvasc (Amlodipine Besilate)	C				
			Cardura (Doxazosin Mesilate)	C				
			Exelon (Rivastigmine Tartrate)	C				
			Aricept (Donepezil Hydrochloride)	C				
			Risperdal (Risperidone)	C				
			Succinate)	C				
			Lasix (Furosemide)	C				
			Digoxin (Digoxin)	C				
			Coumadin (Warfarin Sodium)	C				
			Amiodarone (Amiodarone Synthroid (Levothyroxine Sodium))	C				
			Buspar (Buspirone Hydrochloride)	C				
			Nitro Patch (Glyceryl Trinitrate)	C				
			Asendin (Amoxapine)	C				
			Risperdal (Risperidone)	C				

Date: 01/05/01 **ISR Number:** 3642824-4 **Report Type:** Expedited (15-Day) **Company Report#:** DRON00200006747 **Age:** 70 YR **Gender:** Male **I/FU:** 1

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Femur Fracture	Study Health Professional	Marinol	PS	Unimed Inc	ORAL	2.5 MG BID PO	
			Norvasc (Amlodipine Besilate)	C				
			Cardura (Doxazosin Mesilate)	C				
			Exelon (Rivastigmine Tartrate)	C				
			Aricept (Donepezil Hydrochloride)	C				
			Risperdal (Risperidone)	C				

Date: 01/05/01 **ISR Number:** 3642827-X **Report Type:** Expedited (15-Day) **Company Report#:** DRON00200006695 **Age:** 92 YR **Gender:** Female **I/FU:** 1

Date: 01/12/01 **ISR Number:** 3647338-3 **Report Type:** Expedited (15-Day) **Company Report#:** DRON00200006511 **Age:** 82 YR **Gender:** Male **I/FU:** F

Outcome Hospitalization - Initial or Prolonged
PT Abdominal Pain Upper
 Asthenia
 Blood Glucose Increased
 Blood Pressure Systolic Increased
 Chest Pain
 Convulsion
 Gastritis
 Hypersomnia
 Medication Error
 Oedema

**FDA - Adverse Event Reporting System (AERS)
Freedom Of Information (FOI) Report**

Pallor
Pancreatitis
Tremor
Vomiting

Report Source
Study Health Professional

Product
Marinol
Exelon (Rivastigmine Tartrate)
Zolof
Pepticid

Role
PS
SS
C
C

Manufacturer
Unimed Inc

Route
ORAL
ORAL

Dose
SEE IMAGE
4.5 MG BID PO

Duration

Date: 01/16/01 ISR Number: 3648820-5 Report Type: Expedited (15-Day) Company Report#: DRON00200006695 Age: 92 YR Gender: Female I/FU: F

PT
Fall
Femur Fracture
Insomnia
Oedema Peripheral

Report Source
Study Health Professional

Product
Marinol

Role
PS

Manufacturer
Unimed Inc

Route
ORAL

Dose
2.5 MG BID PO

Duration

Date: 01/18/01 ISR Number: 3651010-3 Report Type: Expedited (15-Day) Company Report#: DRON00200006747 Age: 70 YR Gender: Male I/FU: F

PT
Abnormal Behaviour
Myocardial Infarction

Report Source
Study Health Professional

Product
Marinol
Norvasc
Cardura
Exelon
Ariccept
Risperdal
Nitro-Dur
Ecotrin

Role
PS
C
C
C
C
C
C

Manufacturer
Unimed Inc

Route
ORAL

Dose
5MG, 2.5MG
BID PO

Duration

Date: 01/26/01 ISR Number: 3656012-9 Report Type: Expedited (15-Day) Company Report#: DRON00200006695 Age: 92 YR Gender: Female I/FU: F

PT
Fall
Femur Fracture

Report Source
Study Health Professional

Product
Marinol
Duragesic (Fentanyl)
Restoril (Temazepam)
Dyazide ()

Role
PS
C
C
C

Manufacturer
Unimed Inc

Route
ORAL

Dose
2.5 MG BID PO

Duration

Date: 01/26/01 ISR Number: 3656016-6 Report Type: Expedited (15-Day) Company Report#: DRON00200006511 Age: 82 YR Gender: Male I/FU: F

PT
Abdominal Pain Upper
Asthenia
Blood Glucose Increased
Blood Pressure Increased
Chest Pain
Convulsion
Gastritis
Gastroesophageal Reflux
Disease
Hypersomnia
Leukocytosis
Medication Error

Report Source
Study Health Professional

Product
Marinol
Duragesic (Fentanyl)
Restoril (Temazepam)
Dyazide ()

Role
PS
C
C
C

Manufacturer
Unimed Inc

Route
ORAL

Dose
2.5 MG BID PO

Duration

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

Nausea	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Oedema	Study	Marinol	PS	Unimed Inc	ORAL	5 MG BID PO, 5 MG DAILY PO	
Pallor	Health	Exelon (Rivastigmine Tartrate)	SS		ORAL	4.5 MG BID PO, 1.5 MG BID PO	
Pancreatitis	Professional	Zoloft (Sertraline Hydrochloride)	C				
Tremor		Peppid (Famotidine)	C				
Vomiting		Exelon (Rivastigmine Tartrate)	C				

Date: 01/31/01 ISR Number: 3658304-6 Report Type: Expedited (15-Day) Company Report#: DRON00201000231 Age: 62 YR Gender: Female I/FU: I

Outcome	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Study	Marinol	PS	Unimed Inc	ORAL	2.5 MG BID PO	
Initial or Prolonged	Health	Detrol (Tolterodine L-Tartrate)	C				
	Professional	Zyprexa (Olanzapine)	C				
		Exelon	C				

Date: 02/20/01 ISR Number: 3668361-9 Report Type: Expedited (15-Day) Company Report#: DRON00200006747 Age: 70 YR Gender: Male I/FU: F

Outcome	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Life-Threatening	Study	Marinol	PS	Unimed Inc	ORAL	5 MG BID PO, 2.5 MG BID PO, 2.5 MG BID PO	
Hospitalization -	Health	Norvasc (Amlodipine Besilate)	C				
Initial or Prolonged	Professional	Cardura (Doxazosin Mesilate)	C				
		Exelon (Rivastigmine Tartrate)	C				
		Aricept (Donepezil Hydrochloride)	C				
		Risperdal (Risperidone)	C				
		Nitro-Dur (Glyceryl Trinitrate)	C				
		Ecotrin (Acetylsalicylic Acid)	C				

Date: 02/21/01 ISR Number: 3668923-9 Report Type: Periodic Company Report#: PHEH2000US11513 Age: 81 YR Gender: Male I/FU: I

Outcome	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization -	Study						
Initial or Prolonged	Health						
	Professional						

**FDA - Adverse Event Reporting System (AERS)
Freedom Of Information (FOI) Report**

Overdose
Sedation
Tremor
Vomiting

Report Source
Health Professional

Product
Exelon

Role
PS

Manufacturer
Novartis Pharmaceuticals Corp

Route
ORAL

Dose
4.5 MG, BID,
ORAL

Duration
41 DAY

Marinol (Dronabinol)
Zoloft (Sertraline)
Hydrochloride)
Compazine
(Prochlorperazine
Edisylate)

SS
C
C

Date: 05/21/01 **ISR Number:** 3727116-7 **Report Type:** Periodic **Company Report#:** PHEH2000US11513 **Age:** 81 YR **Gender:** Male **I/FU:** F

Outcome
Hospitalization -
Initial or Prolonged

PT
Abdominal Pain Upper
Chest Pain
Nausea
Oedema
Overdose
Sedation
Tremor
Vomiting

Report Source
Health Professional

Product
Exelon

Role
PS

Manufacturer
Novartis Pharmaceuticals Corp

Route
ORAL

Dose
4.5 MG; 1.5
MG, BID, ORAL

Duration
41 DAY

Marinol (Dronabinol)
Zoloft (Sertraline)
Hydrochloride)
Compazine
(Prochlorperazine
Edisylate)

SS
C
C

Date: 05/28/01 **ISR Number:** 3728938-9 **Report Type:** Direct **Company Report#:** **Age:** 23 YR **Gender:** Female **I/FU:** I

Outcome
Other

PT
Dyskinesia
Eye Movement Disorder

Report Source

Product
Marinol, 5mg,
Unlimited
Pharmaceutical

Role
PS

Manufacturer
Unlimited
Pharmaceutical

Route
ORAL

Dose
5MG, TID,
ORAL

Date: 06/12/01 **ISR Number:** 3757303-3 **Report Type:** Periodic **Company Report#:** DRON00201000333 **Age:** **Gender:** Male **I/FU:** I

Outcome
Other

PT
Emotional Disorder
Malaise
Nausea

Report Source
Consumer

Product
Marinol

Role
PS

Manufacturer
Unimed Inc

Route
ORAL

Dose
DAILY PO

Duration

Date: 07/12/01 **ISR Number:** 3757300-8 **Report Type:** Periodic **Company Report#:** DRON00201000622 **Age:** 39 YR **Gender:** Male **I/FU:** I

Outcome
Other

PT
Headache

Report Source
Consumer

Product
Marinol

Role
PS

Manufacturer
Unimed Inc

Route
ORAL

Dose
5 MG DAILY PO

Duration

**FDA - Adverse Event Reporting System (AERS)
Freedom Of Information (FOI) Report**

<u>Date:</u> 07/12/01	<u>ISR Number:</u> 3757314-8	<u>Report Type:</u> Periodic	<u>Company Report#:</u> DRON00201000633	<u>Product</u> Marinol Zoloft (Sertraline Hydrochloride) Klonopin (Clonazepam)	<u>Role</u> PS C C	<u>Manufacturer</u> Unimed Inc	<u>Route</u> ORAL	<u>Dose</u> 10 MG BID PO	<u>Gender:</u> Female	<u>I/FU:</u> 1
<u>Outcome</u> Other	<u>PT</u> Skin Discolouration		<u>Report Source</u> Consumer							
<u>Date:</u> 07/12/01	<u>ISR Number:</u> 3757319-7	<u>Report Type:</u> Periodic	<u>Company Report#:</u> DRON00201001512	<u>Product</u> Marinol	<u>Role</u> PS	<u>Manufacturer</u> Unimed Inc	<u>Route</u> ORAL	<u>Dose</u> DAILY PO	<u>Gender:</u> Male	<u>I/FU:</u> 1
<u>Outcome</u> Other	<u>PT</u> Drug Ineffective		<u>Report Source</u> Health Professional							
<u>Date:</u> 07/12/01	<u>ISR Number:</u> 3757324-0	<u>Report Type:</u> Periodic	<u>Company Report#:</u> DRON00201001644	<u>Product</u> Marinol	<u>Role</u> PS	<u>Manufacturer</u> Unimed Inc	<u>Route</u> ORAL	<u>Dose</u> DAILY PO	<u>Gender:</u> Male	<u>I/FU:</u> 1
<u>Outcome</u> Other	<u>PT</u> Dyspepsia		<u>Report Source</u> Health Professional							
<u>Date:</u> 07/12/01	<u>ISR Number:</u> 3757329-X	<u>Report Type:</u> Periodic	<u>Company Report#:</u> DRON00201001675	<u>Product</u> Marinol	<u>Role</u> PS	<u>Manufacturer</u> Unimed Inc	<u>Route</u> ORAL	<u>Dose</u> 10 MG BID PO, 5 MG BID PO	<u>Gender:</u> Female	<u>I/FU:</u> 1
<u>Outcome</u> Other	<u>PT</u> Dizziness Therapeutic Response Unexpected		<u>Report Source</u> Consumer							
<u>Date:</u> 07/12/01	<u>ISR Number:</u> 3757349-5	<u>Report Type:</u> Periodic	<u>Company Report#:</u> DRON00201002225	<u>Product</u> Marinol Betapace (Sotalol Hydrochloride) Warfarin (Warfarin)	<u>Role</u> PS C C	<u>Manufacturer</u> Unimed Inc	<u>Route</u> ORAL	<u>Dose</u> 10 MG QD PO	<u>Gender:</u> Male	<u>I/FU:</u> 1
<u>Outcome</u> Other	<u>PT</u> Annesia Dizziness Speech Disorder		<u>Report Source</u> Consumer							
<u>Date:</u> 07/12/01	<u>ISR Number:</u> 3757371-9	<u>Report Type:</u> Periodic	<u>Company Report#:</u> DRON00201002525	<u>Product</u> Marinol Viracept (Nelfinavir Mesilate) Cytovene (Ganciclovir Sodium) Epivir (Lamivudine) Fortovase (Saquinavir) Videx (Didanosine) Bactrim (Bactrim) Imodium (Loperamide Hydrochloride)	<u>Role</u> PS C C C C C C C C	<u>Manufacturer</u> Unimed Inc	<u>Route</u> ORAL	<u>Dose</u> 5 G DAILY PO	<u>Gender:</u> Female	<u>I/FU:</u> 1
<u>Outcome</u> Other	<u>PT</u> Anorexia Depression Emotional Disorder Personality Disorder		<u>Report Source</u> Health Professional							

**FDA - Adverse Event Reporting System (AERS)
Freedom Of Information (FOI) Report**

Date: 08/14/01 **ISR Number:** 3777366-9 **Report Type:** Expedited (15-Day) **Company Report#:** BLND00201003509 **Age:** 45 YR **Gender:** Male **IFU:** I

Outcome Hospitalization - Initial or Prolonged	PT Constipation Intestinal Obstruction Vomiting	Report Source Foreign Health Professional	Product Marinol Baclofen Tizanidine Amitriptyline Clonazepam Oxybutynin Spasmonal (Alverine Citrate) Rabeprazole	Role PS C C C C C C C	Manufacturer Unimed Inc	Route ORAL	Dose 10 DAILY PO	Duration
---	---	---	---	--	-----------------------------------	----------------------	----------------------------	-----------------

Date: 10/11/01 **ISR Number:** 3807590-8 **Report Type:** Direct **Company Report#:**

Outcome Hospitalization - Initial or Prolonged	PT Hallucination	Report Source	Product Dronabinol	Role PS	Manufacturer	Route	Dose	Duration
---	----------------------------	----------------------	------------------------------	-------------------	---------------------	--------------	-------------	-----------------

Date: 10/22/01 **ISR Number:** 3812656-2 **Report Type:** Expedited (15-Day) **Company Report#:** DRON00201000256 **Age:** 79 YR **Gender:** Female **IFU:** I

Outcome Hospitalization - Initial or Prolonged	PT Agitation Anaemia Blood Creatine Phosphokinase Increased Blood Thyroid Stimulating Hormone Increased	Report Source Study Health Professional	Product Compassia (Dronabinol) Synthroid (Levothyroxine Sodium)	Role PS C	Manufacturer	Route ORAL	Dose 2.5 MG BID PO	Duration
---	--	---	---	------------------------	---------------------	----------------------	------------------------------	-----------------

Date: 10/22/01 **ISR Number:** 3812711-7 **Report Type:** Expedited (15-Day) **Company Report#:** DRON00201001964 **Age:** 88 YR **Gender:** Male **IFU:** I

Outcome Death Hospitalization - Initial or Prolonged	PT Atrophy Brain Herniation Fall Haemorrhagic Stroke Head Injury Nervous System Disorder Pulse Absent	Report Source Study Health Professional	Product Marinol (Dronabinol) Enalapril (Enalapril) Coumadin (Warfarin Sodium) Primivil (Lisinopril) Lasix (Furosemide) Mevacor (Lovastatin) Pepcid (Famotidine) Xanax (Alprazolam) Valium (Diazepam)	Role PS C C C C C C C C	Manufacturer	Route ORAL	Dose 5 MG BID PO	Duration
--	---	---	---	---	---------------------	----------------------	----------------------------	-----------------

**FDA - Adverse Event Reporting System (AERS)
Freedom Of Information (FOI) Report**

Date: 12/10/02 ISR Number: 4024891-1 Report Type: Expedited (15-Day) Company Report#: PHNU2002DE03089

Age: Unknown I/FU: F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Drug Interaction Muscle Spasticity	Foreign Health Professional Other	Lioresal (Baclofen) Tablet Dronabinol (Dronabinol)	PS SS		ORAL	ORAL CHANGING DOSAGE	
			Mydocalm "Strathmann" (Tolperisone Hydrochloride)	C C C				
			Sirdalud Benzodiazepines	C C				

Date: 02/21/03 ISR Number: 4059171-1 Report Type: Direct Company Report#: CTU 187090

Age: Male I/FU: I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Mental Status Changes		Dronabinol 2.5 Mg	PS		ORAL	2.5 MG BID ORAL	
			Asa Calcium Docusate Erythromycin Fluoxetine Gabapentin Hydralazine Insulin Lisinopril Metoprolol Nepirocap Pyridoxine Rabeprazole Simvastatin Sodium Bicarbonate Clonidine Patch	C C C C C C C C C C C C C C C C				

Date: 04/22/03 ISR Number: 4100581-1 Report Type: Expedited (15-Day) Company Report#: DRON00203000912

Age: 50 YR Gender: Female I/FU: I

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Other	Confusional State Contusion Fall Haemorrhagic Stroke Metastases To Central Nervous System Speech Disorder	Health Professional	Marinol (Dronabinol) Oxycontin (Oxycodone Hydrochloride) Wellbutrin (Amfebutamone Hydrochloride) Misir (Morphine Sulfate)	PS C C C		ORAL	2.5 MG TID PO	

Date: 06/18/03 ISR Number: 4132616-4 Report Type: Expedited (15-Day) Company Report#: DRON00203000912

Age: 50 YR Gender: Female I/FU: F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Death Hospitalization - Initial or Prolonged	Cerebellar Infarction Cerebral Artery Occlusion Cerebral Ischaemia							

**FDA - Adverse Event Reporting System (AERS)
Freedom Of Information (FOI) Report**

Contusion	<u>Report Source</u>	<u>Product</u>	<u>Role</u>	<u>Manufacturer</u>	<u>Route</u>	<u>Dose</u>	<u>Duration</u>
Demyelination	Health	Marinol (Dronabinol)	PS		ORAL	5 MG DAILY PO	
Eye Swelling	Professional	Oxycontin (Oxycodone Hydrochloride)	C				
Fall		Wellbutrin					
Metastases To Spine		(Amfebutamone Hydrochloride)	C				
Nerve Root Compression		Msir (Morphine Sulfate)	C				
Spinal Compression		Ativan (Lorazepam)	C				
Fracture		Ambien (Zolpidem Tartrate)	C				
		Lidoderm (Lidoderm)	C				
		Vioxx (Rofecoxib)	C				

Date: 06/18/03 ISR Number: 4132622-X Report Type: Expedited (15-Day) Company Report#: DRON00203001454

Age: 70 YR Gender: Male I/FU: 1

<u>Outcome</u>	<u>Report Source</u>	<u>Product</u>	<u>Role</u>	<u>Manufacturer</u>	<u>Route</u>	<u>Dose</u>	<u>Duration</u>
Hospitalization - Initial or Prolonged	Health	Marinol (Dronabinol)	PS		ORAL	2.5 MG BID PO	
	Professional	Topamax (Topiramate)	C				
	Company	Lamical					
	Representative	(Lamotrigine)	C				

Date: 06/18/03 ISR Number: 4132624-3 Report Type: Expedited (15-Day) Company Report#: DRON00203001453

Age: 49 YR Gender: Female I/FU: 1

<u>Outcome</u>	<u>Report Source</u>	<u>Product</u>	<u>Role</u>	<u>Manufacturer</u>	<u>Route</u>	<u>Dose</u>	<u>Duration</u>
Hospitalization - Initial or Prolonged	Health	Marinol (Dronabinol)	PS		ORAL	2.5 MG BID PO	
	Professional	Elavil					
	Company	(Amitriptyline Hydrochloride)	C				
	Representative	Dilantin (Phenytoin Sodium)	C				
		Unknown Hiv Medications (Unknown Hiv Medications)	C				

Date: 06/27/03 ISR Number: 4139163-4 Report Type: Expedited (15-Day) Company Report#: DRON00203001281

Age: 51 YR Gender: Male I/FU: 1

<u>Outcome</u>	<u>Report Source</u>	<u>Product</u>	<u>Role</u>	<u>Manufacturer</u>	<u>Route</u>	<u>Dose</u>	<u>Duration</u>
Other	Health	Marinol (Dronabinol)	PS		ORAL	5 MG DAILY PO	
	Professional	Keppra	C				
	Company	(Levetiracetam)					
	Representative	Decadron	C				
		(Dexamethasone)	C				
		Peptic (Famotidine)	C				
		Sulfasalazin	C				
		(Sulfasalazine)					

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

<u>Date</u>	<u>IS</u> <u>SR</u> <u>Number</u>	<u>Report</u> <u>Type</u>	<u>Expedited</u> <u>(15-Day)</u>	<u>Company</u> <u>Report#</u>	<u>Product</u>	<u>Role</u>	<u>Manufacturer</u>	<u>Route</u>	<u>Age</u>	<u>Gender</u>	<u>F</u> <u>M</u> <u>I</u>	<u>Dose</u>	<u>Duration</u>
06/30/03	4139652-2	PT Pituitary Tumour Benign	Expedited	DRON00203001595	Marinol (Dronabinol) Elavil (Amitriptyline Hydrochloride) Klonopin (Clonazepam)	PS C C		ORAL		Female	I	DAILY PO	
07/15/03	4149082-5	PT Convulsion	Expedited	DRON00201000636	Marinol (Dronabinol)	PS		ORAL		Female	I	2.5 MG BID; PO	
07/25/03	4157631-6	PT Convulsion	Expedited	DRON00203001454	Marinol (Dronabinol) Topamax (Topiramate) Lamictal (Lamotrigine) Trileptal (Oxcarbazepine) Prevacid (Lansoprazole) Zoloft (Sertraline Hydrochloride) Bactrim Azithromycin (Azithromycin) Vasotec (Enalapril Maleate) Daraprim (Pyrimethamine) Leucovorin (Leucovorin)	PS C C C C C C C C C C C C C C C C		ORAL	70 YR	Male	F	2.5 MG BID PO	
07/25/03	4157633-X	PT Coma Convulsion Drug Interaction Drug Screen Positive Respiratory Depression	Expedited	DRON00203001453	Marinol (Dronabinol) Elavil (Amitriptyline Hydrochloride) Dilantin (Phenytoin Sodium) Unknown Hiv Medications (Unknown Hiv Medications) Norvir (Ritonavir) Fortovase (Saquinavir) Ziagen (Abacavir)	PS C C C C C C C		ORAL	49 YR	Female	F	2.5 MG BID PO	

**FDA - Adverse Event Reporting System (AERS)
Freedom Of Information (FOI) Report**

Epivir (Lamivudine) C
 Daraprim (Pyrimethamine) C
 Leucovorin (Leucovorin) C
 Aldactone (Spironolactone) C
 Duragesic Patches (Fentanyl) C
 Percocet (Percocet) C

Date: 07/30/03 **ISR Number:** 4164677-0 **Report Type:** Periodic **Company Report#:** DRON00202002202 **Age:** 37 YR **Gender:** Female **I/FU:** 1

Outcome: Hospitalization - Initial or Prolonged **PT:** Abortion Spontaneous **Report Source:** Consumer **Product:** Marinol (Dronabinol) **Role:** PS **Manufacturer:** **Route:** ORAL **Dose:** 5 MG TID PO **Duration:**

Date: 08/04/03 **ISR Number:** 4163796-2 **Report Type:** Expedited (15-Day) **Company Report#:** 2003012192 **Age:** 73 YR **Gender:** Male **I/FU:** 1

Outcome: Death **PT:** Dizziness Drug Interaction **Report Source:** Consumer Health Professional **Product:** Tikosyn (Dofetilide) **Role:** PS **Manufacturer:** **Route:** **Dose:** 1000 MCG (BID) 2.5 MG (PRN)

Dronabinol (Dronabinol) SS
 Stavudine (Stavudine) C
 Lamivudine (Lamivudine) C
 Nevirapine (Nevirapine) C
 Losartan Potassium (Losartan Potassium) C
 Carvedilol (Carvedilol) C
 Furosemide (Furosemide) C
 Potassium (Potassium) C
 Warfarin (Warfarin) C
 Loperamide (Loperamide) C
 Ipratropium Bromide (Ipratropium Bromide) C
 Salmeterol (Salmeterol) C
 Xinafoate (Xinafoate) C

Date: 09/11/03 **ISR Number:** 4200786-5 **Report Type:** Periodic **Company Report#:** 2003164678US **Age:** 37 YR **Gender:** Male **I/FU:** 1

Outcome: Hospitalization - Initial or Prolonged **PT:** Asthenia Difficulty In Walking Flushing

**FDA - Adverse Event Reporting System (AERS)
Freedom Of Information (FOI) Report**

<u>Report Source</u>	<u>Product</u>	<u>Role</u>	<u>Manufacturer</u>	<u>Route</u>	<u>Dose</u>	<u>Duration</u>
Muscle Twitching Myalgia Nausea Renal Failure Acute Somnolence Vomiting	Bextra (Valdecoxib) Tablet	PS		ORAL	UNK, UNK; ORAL	
	Celebrex (Celecoxib, Celecoxib) Capsule Viread (Tenofovir)	SS SS		UNKNOWN UNKNOWN	UNK, UNK, UNK 300 UNK, UNK, UNK	
	Fortovase (Saqina vir) Zerit (Stavudine) Kaletra (Lopinavir/Ritonavir)	SS SS		UNKNOWN	UNK, UNK, UNK UNK, UNK, UNK	
	Phenergan (Promethazine)	SS		UNKNOWN	UNK, UNK, UNK	
	Ambien (Zolpidem Tartrate)	SS		UNKNOWN	UNK, UNK, UNK	
	Ensure (Vitamins Nos)	SS		UNKNOWN	UNK, UNK, UNK	
	Tricor (Fenofibrate)	SS		UNKNOWN	UNK, UNK, UNK	
	Dulcolax (Bisacodyl)	SS		UNKNOWN	UNK, UNK, UNK	
	Marinol (Dronabinol)	SS		UNKNOWN	UNK, UNK, UNK	
	Soma (Carisoprodol)	SS		UNKNOWN	UNK, UNK, UNK	
	Bactrim Ds (Sulfamethoxazole Trimethoprim)	SS		UNKNOWN	UNK, UNK, UNK	
	Biaxin (Clarithromycin)	SS		UNKNOWN	UNK, UNK, UNK	
	Protonix ()	SS		UNKNOWN	UNK, UNK, UNK	
	Oxandrin (Oxandrolone)	SS		UNKNOWN	UNK, UNK, UNK	
	Neurontin (Gabapentin)	SS		UNKNOWN	UNK, UNK, UNK	
	Colchicine (Colchicine)	SS		UNKNOWN	UNK, UNK, UNK	

Date: 09/30/03 ISR Number: 4202995-8 Report Type: Expedited (15-Day) Company Report#: DRON00203002664

<u>Outcome</u>	<u>PT</u>	<u>Report Source</u>	<u>Product</u>	<u>Role</u>	<u>Manufacturer</u>	<u>Age:</u>	<u>Gender:</u>	<u>I/FU:</u>
Other	Hypersomnia	Health Professional Company Representative	Marinol (Dronabinol)	PS		ORAL	Female	I
							Dose 5 MG TID PO	Duration

Date: 10/29/03 ISR Number: 4223679-6 Report Type: Expedited (15-Day) Company Report#: K11-2003-0004100

<u>Outcome</u>	<u>PT</u>	<u>Report Source</u>	<u>Product</u>	<u>Role</u>	<u>Manufacturer</u>	<u>Age:</u>	<u>Gender:</u>	<u>I/FU:</u>
Hospitalization - Initial or Prolonged Other	Abnormal Behaviour Agitation Blood Ph Increased Delusion Depressed Level Of Consciousness Hypotonia	Health Professional Company Representative	Marinol (Dronabinol)	PS		ORAL	Female	I

**FDA - Adverse Event Reporting System (AERS)
Freedom Of Information (FOI) Report**

Date: 07/16/04 **ISR Number:** 4406642-1 **Report Type:** Expedited (15-Day) **Company Report#:** DRON00204002327 **Age:** 50 YR **Gender:** Female **I/FU:** F

<u>Outcome</u>	<u>PT</u>	<u>Report Source</u>	<u>Product</u>	<u>Role</u>	<u>Manufacturer</u>	<u>Route</u>	<u>Dose</u>	<u>Duration</u>
Other	Circulatory Collapse Confusional State Somnolence Speech Disorder	Foreign Study Health Professional Other	Marinol (Dronabinol)	PS		ORAL	2.5 MG BID, PO	
			Amiriprytline (Amiriprytline)	SS		ORAL	200 MG DAILY PO	
			Baclofen (Baclofen)	SS		ORAL	70 MG DAILY PO	
			Tizanidine (Tizanidine)	SS		ORAL	32 MG DAILY PO	

Date: 07/19/04 **ISR Number:** 4402771-7 **Report Type:** Expedited (15-Day) **Company Report#:** DRON00204000324 **Age:** 58 YR **Gender:** Female **I/FU:** 1

<u>Outcome</u>	<u>PT</u>	<u>Report Source</u>	<u>Product</u>	<u>Role</u>	<u>Manufacturer</u>	<u>Route</u>	<u>Dose</u>	<u>Duration</u>
Hospitalization - Initial or Prolonged	Blood Pressure Diastolic Decreased Dizziness Fatigue Feeling Abnormal Nausea Oral Intake Reduced Syncope	Study Health Professional	Marinol (Marinol)	PS		ORAL	2.5 MG BID PO, SEE IMAGE	
			Ondansetron (Ondansetron)	SS		INTRAVENOUS	16 MG DAILY IV, SEE IMAGE	
			Dexamethasone (Dexamethasone)	SS		ORAL	20 MG DAILY PO	
			Vitamin C	C				
			Glucosamine	C				
			Calcium	C				
			Folic Acid	C				
			Centrum	C				
			Lisinopril	C				
			Hydrochlorothiazide	C				
			Vitamin E	C				
			Aspirine (Acetylsalicylic Acid)	C				

Date: 07/19/04 **ISR Number:** 4402773-0 **Report Type:** Expedited (15-Day) **Company Report#:** DRON00204001114 **Age:** 64 YR **Gender:** Male **I/FU:** 1

<u>Outcome</u>	<u>PT</u>	<u>Report Source</u>	<u>Product</u>	<u>Role</u>	<u>Manufacturer</u>	<u>Route</u>	<u>Dose</u>	<u>Duration</u>
Hospitalization - Initial or Prolonged	Blood Creatinine Increased Chest Pain Febrile Neutropenia Gastroesophageal Reflux Disease Muscle Spasms Pancytopenia White Blood Cell Count Increased	Study Health Professional	Marinol (Dronabinol)	PS		ORAL	2 DF DAILY PO	
			Ondansetron (Ondansetron)	SS		INTRAVENOUS	16 MG ONCE IV	
			Dexamethasone (Dexamethasone)	SS		ORAL	20 MG ONCE PO	
			Carboplatin (Carboplatin)	SS		INTRAVENOUS	465 MG ONCE IV	
			Genzar (Gencitabine Hydrochloride)	SS		INTRAVENOUS	1830 MG ONCE IV, 1830 MG ONCE IV	
			Verapamil	C				
			Glucotrol (Glipizide)	C				
			Lisinopril	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

<u>Date</u>	<u>ISR Number</u>	<u>Report Type</u>	<u>Expedited (15-Day) Company Report#</u>	<u>Product</u>	<u>Report Source</u>	<u>Role</u>	<u>Manufacturer</u>	<u>Route</u>	<u>Dose</u>	<u>Gender</u>	<u>Age</u>	<u>YR</u>	<u>IFU</u>
07/19/04	4403798-1	PT Chest Pain Headache	Expedited (15-Day)	Marinol (Dronabinol)	Study Health Professional	PS		ORAL	2.5 MG BID PO	Female	53		I
07/23/04	4408644-8	PT Multiple Sclerosis Relapse Urinary Tract Infection	Expedited (15-Day)	Marinol (Marinol) Baclofen (Baclofen) Propranolol Prozac (Fluoxetine) Hydrochloride Quinine Sulfate Zopiclone Tolterodine	Foreign Study Health Professional Other	PS C C C C C C		ORAL	8 DF DAILY PO	Male	49		I
07/23/04	4409729-2	PT Anaemia Biopsy Bone Marrow Abnormal Nausea Pneumonia Klebsiella Pneumonitis Sepsis Vomiting	Expedited (15-Day)	Marinol (Dronabinol) Dexamethasone (Dexamethasone) Ondansetron (Ondansetron) Fosinopril (Fosinopril) Adalat (Nifedipine) Metformin (Metformin) Terazosin (Terazosin)	Study Health Professional	PS SS SS C C C C		ORAL ORAL INTRA VENOUS	2.5 MG BID PO, 2.5 MG QID PO 20 MG ONCE PO 16 MG ONCE IV	Male	75		I
08/05/04	4423253-2	PT Blood Potassium Decreased Chest Pain Glycosylated Haemoglobin Increased Haemoglobin Decreased Headache	Expedited (15-Day)	Marinol (Dronabinol) Ondansetron (Ondansetron) Dexamethasone (Dexamethasone) Ultracet (Tramadol) Novolin (Insulin)	Study Health Professional	PS SS SS C C		ORAL INTRA VENOUS ORAL	2.5 MG BID PO 16 MG ONCE IV 20 MG DAILY PO	Female	53		F

**FDA - Adverse Event Reporting System (AERS)
Freedom Of Information (FOI) Report**

Date: 08/17/04 ISR Number: 4431000-3 Report Type: Expedited (15-Day) Company Report#: DRON00204001047

Age: 53 YR Gender: Female IFU: F

<u>PT</u>	<u>Report Source</u>	<u>Product</u>	<u>Role</u>	<u>Manufacturer</u>	<u>Route</u>	<u>Dose</u>	<u>Duration</u>
Back Pain	Study	Marinol (Dronabinol)	PS		ORAL	2.5 MG BID PO	
Blood Potassium Decreased	Health	Ondansetron	SS		INTRAVENOUS	16 MG ONCE IV	
Chest Pain	Professional	Dexamethasone (Dexamethasone)	SS		ORAL	20 MG DAILY PO	
Glycosylated Haemoglobin Increased		Ultracet (Tramadol)	C				
Haemoglobin Decreased		Novolin (Insulin)	C				
Headache							
Myocardial Infarction							
Prothrombin Time Prolonged							

Date: 08/24/04 ISR Number: 4433273-X Report Type: Expedited (15-Day) Company Report#: DRON00204002739

Age: 51 YR Gender: Male IFU: I

<u>PT</u>	<u>Report Source</u>	<u>Product</u>	<u>Role</u>	<u>Manufacturer</u>	<u>Route</u>	<u>Dose</u>	<u>Duration</u>
Blood Glucose Increased	Health	Marinol (Dronabinol)	PS		ORAL	DAILY PO	
Blood Magnesium Decreased	Professional	Aranesp (Aranesp)	SS		SUBCUTANEOUS	200 IU QD SC	
Blood Sodium Decreased		Kytril (Granisetron)	SS		INTRAVENOUS	1 MG QD IV	
Confusional State		Oxycontin (Oxycodone Hydrochloride)	SS		ORAL	20 MG BID PO	
Contusion		Neurontin	SS		ORAL	DAILY PO	
Convulsion		(Gabapentin)	SS		ORAL	DAILY PO	
Eye Injury		Aricept (Donepezil Hydrochloride)	SS		ORAL	DAILY PO	
Face Injury		Morphine Sulfate	C				
Fall		Chlorpromazine	C				
Gastrointestinal Haemorrhage		(Chlorpromazine)	C				
Haemolytic Anaemia		Oxycodone	C				
Liver Transplant		(Oxycodone)	C				
Rejection		Prograf (Prograf)	C				
Mental Status Changes		Protonix (Protonix)	C				
Metabolic Encephalopathy		Prandin "Kuhni"	C				
Nausea		(Deflazacort)	C				
Pancytopenia		Zoloft (Sertraline Hydrochloride)	C				
Vomiting		Hydrochloride	C				
		Glipizide	C				
		Procardia	C				
		(Nifedipine)	C				
		Magnesium	C				
		(Magnesium)	C				
		Levaquin	C				
		(Levofloxacin)	C				
		Pentamidine	C				
		(Pentamidine)	C				
		Pericolace	C				
		(Pericolace)	C				
		Dulcolax (Bisacodyl)	C				
		Asa (Acetylsalicylic Acid)	C				
		Lasix (Lasix)	C				
		Leukine	C				
		(Sargramostim)	C				
		Dexamethasone	C				
		(Dexamethasone)	C				
		Adriamycin	C				

FDA - Adverse Event Reporting System (AERS)

Freedom Of Information (FOI) Report

(Doxorubicin)
 Cisplatinum
 (Cisplatin)
 Senecot (Senecot)
 Inderal (Inderal)
 Multivitamins
 (Multivitamins)
 Insulin (Insulin)
 Aldactone
 (Aldactone)
 Megace (Megace)

Date: 08/30/04 ISR Number: 4439646-3 Report Type: Expedited (15-Day) Company Report#: USA-2004-0016457

Age: 51 YR Gender: Male I/FU: 1

Outcome Hospitalization - Initial or Prolonged

PT

Blood Glucose Increased
 Blood Magnesium Decreased
 Blood Sodium Decreased
 Confusional State
 Convulsion
 Eye Disorder
 Face Injury
 Fall
 Mental Status Changes
 Nausea
 Pancytopenia
 Vomiting

Report Source

Health Professional
 Other

Product

Oxycontin Tablets
 (Oxycodone Hydrochloride) Cr
 Tablet
 Oxyir Capsules 5
 Mg(Oxycodone Hydrochloride,
 Oxycodone Hydrochloride) Ir
 Aranesp(Darbepoetin)
 Kytril(Granisetron)

Role

PS

Route

INTRAVENOUS

Dose

20 MG, QL2H
 5 MG, Q4H
 1 MG, INTRAVENOUS
 2 MG; 4 MG
 40 MG, DAILY
 81 MG, DAILY
 400 MG

Duration

**FDA - Adverse Event Reporting System (AERS)
Freedom Of Information (FOI) Report**

(Morphine Sulfate) C
 Chlorpromazine C
 (Chlorpromazine) C
 Tacrolimus C
 (Tacrolimus) C
 Pantoprazole C
 (Pantoprazole) C
 Doxorubicin C
 (Doxorubicin) C
 Cisplatin C
 (Cisplatin) C
 Deflazacort C
 (Deflazacort) C
 Senna Fruit (Senna Fruit) C
 Propranolol
 Hydrochloride
 (Propranolol Hydrochloride) C
 Multivitamins
 (Ascorbic Acid, Ergocalciferol, Folic Acid, Nicotinamide, Insulin (Insulin) Spirolactone (Spirolactone) Megestrol Acetate (Megestrol Acetate) Repaglinide (Repaglinide) C

Date: 09/02/04 ISR Number: 4444227-1 Report Type: Expedited (15-Day) Company Report#: A03200402800

Age: 51 YR Gender: Male I/FU: 1

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asithenia	Health Professional	Ambien - Zolpidem Tartrate - Tablet	PS		ORAL	ORAL	
	Confusional State		Aranesp - Darbepoetin Alfa - Solution	SS		SUBCUTANEOUS	SUBCUTANEOUS	
	Convulsion		Marinol - Dronabinol	SS		SUBCUTANEOUS	SUBCUTANEOUS	
	Face Injury		Kytril - Granisetron - Solution - 1 Mg	SS		INTRAVENOUS	1 MG QD - INTRAVENOUS NOS	
	Fall							
	Fatigue							
	Gastrointestinal							
	Haemorrhage							
	Haemolytic Anaemia							
	Liver Transplant							
	Rejection							
	Metabolic Encephalopathy							
	Pancytopenia							
	Swelling							
			Oxycontin - Oxycodone Hydrochloride - 20 Mg	SS			20 MG Q12HR	
			Neurontin - Gabapentin	SS				
			Aricept - Donepezil Hydrochloride	SS				
			Morphine Sulfate	C				
			Chlorpromazine	C				
			Oxycodone	C				
			Tacrolimus	C				
			Pantoprazole	C				
			Deflazacort	C				
			Sertraline	C				

**FDA - Adverse Event Reporting System (AERS)
Freedom Of Information (FOI) Report**

(Spironolactone) SS
 Ambien (Zolpidem Tartrate) SS
 Chlorpromazine (Chlorpromazine) C
 Glipizide (Glipizide) C
 Procardia C
 Pentamidine (Pentamidine) C
 Peri-Colace C
 (Sennoside A+B, Docusate Sodium) C
 Dulcolax C
 Dexamethasone (Dexamethasone) C
 Cis-Platinum (Cisplatin) C
 Zolof (Sertraline Hydrochloride) C
 Leukine C
 (Sargramostim) C
 Adriamycin (Doxorubicin) C

Date: 09/17/04 **ISR Number:** 4452316-0 **Report Type:** Expedited (15-Day) **Company Report#:** US-ROCHE-380104 **Age:** 51 YR **Gender:** Male **I/FU:** 1

<u>Outcome</u>	<u>PT</u>	<u>Report Source</u>	<u>Product</u>	<u>Role</u>	<u>Manufacturer</u>	<u>Route</u>	<u>Dose</u>	<u>Duration</u>
Hospitalization - Initial or Prolonged	Asthma		Granisetron	PS	Roche	UNKNOWN		1 DAY
	Convulsion		Hydrochloride	SS		SUBCUTANEOUS		
	Fall		Darbepeotin Alfa	SS		UNKNOWN		31 DAY
	Fatigue		Dronabinol	SS		UNKNOWN		
	Gastrointestinal		Oxycodone	SS		UNKNOWN		
	Haemorrhage		Gabapentin	SS		UNKNOWN		
	Haemolytic Anaemia		Donepezil	SS		UNKNOWN		
	Head Injury		Hydrochloride	SS		UNKNOWN		
	Liver Transplant		Zolpidem Tartrate	SS		UNKNOWN		
	Rejection		Morphine Sulfate	C		UNKNOWN		
	Mental Status Changes		Chlorpromazine	C		UNKNOWN		
	Metabolic Encephalopathy		Oxvir	C		UNKNOWN		
	Nausea		Tacrolimus	C		UNKNOWN		
	Neuropathy		Pantoprazole	C		UNKNOWN		
	Panycytopenia		Prandin	C		UNKNOWN		
	Swelling		Sertraline	C		UNKNOWN		
	Tremor		Hydrochloride	C		UNKNOWN		
	Vomiting		Glipizide	C		UNKNOWN		
			Nifedipine	C		UNKNOWN		
			Magnesium	C		UNKNOWN		
			Levofloxacin	C		UNKNOWN		8 DAY
			Pentamidine	C		UNKNOWN		
			Pericolace	C		UNKNOWN		
			Bisacodyl	C		UNKNOWN		
			Acetylsalicylic Acid	C		UNKNOWN		
			Frusemide	C		UNKNOWN		1 DAY
			Sargamostim	C		SUBCUTANEOUS		6 DAY
			Dexamethasone	C		UNKNOWN		1 DAY
			Doxorubicin	C		UNKNOWN		
			Cisplatin	C		UNKNOWN		
			Senna Fruit	C		UNKNOWN		
			Propranolol	C		UNKNOWN		

**FDA - Adverse Event Reporting System (AERS)
Freedom Of Information (FOI) Report**

<u>Outcome</u>	<u>PT</u>	<u>Report Source</u>	<u>Product</u>	<u>Role</u>	<u>Manufacturer</u>	<u>Route</u>	<u>Dose</u>	<u>Gender</u>	<u>Age</u>	<u>IFU</u>
			Multivitamins	C						
			Insulin	C						
			Spiromolactone	C						
			Megestrol Acetate	C						
Date: 09/17/04 ISR Number: 4452830-8 Report Type: Expedited (15-Day) Company Report#: 2004057138										
Hospitalization - Initial or Prolonged	Asthma	Consumer Health	Neurontin (Gabapentin)	PS				Male	51 YR	F
Other	Confusional State	Professional	Aricept (Donepezil Hydrochloride)	SS						
	Convulsion		(Donepezil)							
	Fall		Oxycodone	SS			40 MG (20 MG ; 2 IN 1 D)			
	Fatigue		Hydrochloride							
	Mental Status Changes		(Oxycodone Hydrochloride)							
	Nausea		Darbeoetin Alfa (Darbeoetin Alfa)	SS		SUBCUTANEOUS	(200 MCG), SUBCUTANEOUS			
	Pancytopenia		Dronabinol (Dronabinol)	SS						
	Skull X-Ray Abnormal		Granisetron (Granisetron)	SS						
	Swelling									
	Vomiting		Zolpidem Tartrate (Zolpidem Tartrate)	C						
			Sertraline Hydrochloride (Sertraline Hydrochloride)	C						
			Glipizide	C						
			(Glipizide)							
			Nifedipine (Nifedipine)	C						
			Magnesium (Magnesium)	C						
			Levofloxacin (Levofloxacin)	C						
			Pentamidine (Pentamidine)	C						
			Peri-Colace (Casanthranol, Docusate Sodium)	C						
			Bisacodyl (Bisacodyl)	C						
			Acetylsalicylic Acid (Acetylsalicylic Acid)	C						
			Furosemide (Furosemide)	C						
			Sargramostim (Sargramostim)	C						
			Dexamethasone (Dexamethasone)	C						
			Granisetron (Granisetron)	C						
			Morphine Sulfate (Morphine Sulfate)	C						

**FDA - Adverse Event Reporting System (AERS)
Freedom Of Information (FOI) Report**

Chlorpromazine (Chlorpromazine) C
 Tacrolimus C
 Pantoprazole (Pantoprazole) C
 Doxorubicin (Doxorubicin) C
 Cisplatin(Cisplatin) C
 Deflazacort (Deflazacort) C
 Senna Fruit (Sena Fruit) C
 Propranolol Hydrochloride (Propranolol Hydrochloride) C
 Multivitamins (Ascorbic Acid, Ergocalciferol, Folic Acid, Nicotinamide, Insulin (Insulin) C
 Spironolactone (Spironolactone) C
 Megestrol Acetate (Megestrol Acetate) C
 Repaglinide (Repaglinide) C

Date: 10/25/04 ISR Number: 4483544-6 Report Type: Expedited (15-Day) Company Report#: US-SOLVAY-00204003714 Age: 778 MON Gender: Female I/FU: 1

Outcome Hospitalization - Initial or Prolonged	PT Dehydration Drug Ineffective Electrolyte Imbalance	Report Source	Product Marinol	Role PS	Manufacturer	Route ORAL	Dose	Duration 4 DAY
---	--	---------------	--------------------	------------	--------------	---------------	------	-------------------

Date: 10/26/04 ISR Number: 4488958-6 Report Type: Expedited (15-Day) Company Report#: US-SOLVAY-00204003752 Age: Gender: Male I/FU: 1

Outcome Death	PT Death	Report Source	Product Marinol	Role PS	Manufacturer	Route ORAL	Dose Daily dose: unknown	Duration
------------------	-------------	---------------	--------------------	------------	--------------	---------------	--------------------------------	----------

Date: 10/29/04 ISR Number: 4488958-6 Report Type: Expedited (15-Day) Company Report#: US-SOLVAY-00204003714 Age: 778 MON Gender: Female I/FU: 1

Outcome Hospitalization - Initial or Prolonged	PT Dehydration Drug Ineffective Electrolyte Imbalance	Report Source Consumer	Product Marinol	Role PS	Manufacturer	Route ORAL	Dose	Duration 4 DAY
---	--	---------------------------	--------------------	------------	--------------	---------------	------	-------------------

**FDA - Adverse Event Reporting System (AERS)
Freedom Of Information (FOI) Report**

Date: 11/08/04 **ISR Number:** 4495435-5 **Report Type:** Expedited (15-Day) **Company Report#:** US-SOLVAY-00204003858

Age: 28526 **DY** **Gender:** Male **IFU:** I

<u>Outcome</u>	<u>PT</u>	<u>Report Source</u>	<u>Product</u>	<u>Role</u>	<u>Manufacturer</u>	<u>Route</u>	<u>Dose</u>	<u>Duration</u>
Hospitalization - Initial or Prolonged	Dehydration Nausea Vomiting	Marinol	PS		ORAL	Daily dose: 2.5 milligram(s) ONCE	1 DAY	
		Chemotherapy	C	UNKNOWN		Daily dose: unknown		
		Nifedipine	C	ORAL		Daily dose: 1 dosage form		
		Atenolol	C	ORAL		Daily dose: 1 dosage form		
		Simvastatin	C	ORAL		Daily dose: 1 dosage form		

Date: 11/09/04 **ISR Number:** 4501424-4 **Report Type:** Expedited (15-Day) **Company Report#:** DRON00204003858

Age: 78 **YR** **Gender:** Male **IFU:** I

<u>Outcome</u>	<u>PT</u>	<u>Report Source</u>	<u>Product</u>	<u>Role</u>	<u>Manufacturer</u>	<u>Route</u>	<u>Dose</u>	<u>Duration</u>
Hospitalization - Initial or Prolonged	Dehydration Nausea Vomiting	Consumer	Marinol (Dronabinol)	PS	ORAL	2.5 MILLIGRAM (S) QD ORAL		
		Chemotherapy (Chemotherapy)	C					
		Nifedipine	C					
		Atenolol (Atenolol)	C					
		Simvastatin (Simvastatin)	C					

Date: 11/30/04 **ISR Number:** 4513142-7 **Report Type:** Expedited (15-Day) **Company Report#:** US-SOLVAY-00204003714

Age: 787 **MON** **Gender:** Female **IFU:** F

<u>Outcome</u>	<u>PT</u>	<u>Report Source</u>	<u>Product</u>	<u>Role</u>	<u>Manufacturer</u>	<u>Route</u>	<u>Dose</u>	<u>Duration</u>
Hospitalization - Initial or Prolonged	Dehydration Drug Ineffective Electrolyte Imbalance Full Blood Count Abnormal	Marinol	PS		ORAL	Daily dose: 2.5 milligram(s) Daily dose: 10	4 DAY	
		Ambien	C	ORAL		Daily dose: milligram(s)		
		Klonopin	C	ORAL		Daily dose: 1 milligram(s)	61 DAY	
		Ativan	C	ORAL		Daily dose: 3 milligram(s)		
		Metoprolol	C	ORAL		Daily dose: 50 milligram(s)		

Date: 12/16/04 **ISR Number:** 4528499-0 **Report Type:** Expedited (15-Day) **Company Report#:** US-SOLVAY-00204004363

Age: **Gender:** Male **IFU:** I

<u>Outcome</u>	<u>PT</u>	<u>Report Source</u>	<u>Product</u>	<u>Role</u>	<u>Manufacturer</u>	<u>Route</u>	<u>Dose</u>	<u>Duration</u>
Hospitalization - Initial or Prolonged	Chest Pain Cyclic Vomiting Syndrome	Marinol	PS		ORAL	Daily dose: 25 milligram(s) Daily dose: unknown	29 DAY	
		Opioids	C	UNKNOWN				

**FDA - Adverse Event Reporting System (AERS)
Freedom Of Information (FOI) Report**

Outcome Hospitalization - Initial or Prolonged	PT Contusion Face Injury Fall Mental Status Changes	Report Source Study Health Professional	Product	Role	Manufacturer	Route	Dose	Duration
			Insulin	C				
			Aldactone (Spirolactone)	C				
			Megace (Megestrol Acetate)	C				
Date: 02/25/05 ISR Number: 4596128-6 Report Type: Expedited (15-Day) Company Report#: A001-OCT-3720								
			Aricept (Donepezil Hydrochloride)	PS				
			Marinol (Dronabinol)	SS				
			Kytril (Granisetron)	SS		INTRAVENOUS	1 IN 1 D, INTRAVENOUS	
			Oxycontin (Oxycodone Hydrochloride)	SS				1 IN 12 HR
			Neurontin (Gabapentin)	SS				
			Armbien (Zolpidem Tartrate)	SS				
			Aranesp (Darbepoetin Alfa)	C				
			Morphine Sulfate (Morphine Sulfate)	C				
			Chlorpromazine (Chlorpromazine)	C				
			Oxy Ir (Oxycodone Hydrochloride)	C				
			Prograf (Tacrolimus)	C				
			Protonix (Pantoprazole)	C				
			Prandin (Repaglinide)	C				
			Zoloft (Sertraline Hydrochloride)	C				
			Glipizide (Glipizide)	C				
			Procardia (Nifedipine)	C				
			Magnesium (Magnesium)	C				
			Levaquin (Levofloxacin)	C				
			Pentamidine (Pentamidine)	C				
			Pericolace (Peri-Colace)	C				
			Dulcolax Suppository (Bisacodyl)	C				
			Baby Aspirin (Acetylsalicylic Acid)	C				
			Lasix (Furosemide)	C				
			Leukine (Sargramostim)	C				
			Dexamethasone (Dexamethasone)	C				
			Adriamycin (Doxorubicin)	C				

**FDA - Adverse Event Reporting System (AERS)
Freedom Of Information (FOI) Report**

Cisplatinum (C)
 (Cisplatin)
 Senekot (Senna Fruit) (C)
 Inderal (Propranolol Hydrochloride) (C)
 Multivitamins (Multivitamins) (C)
 Insulin (Insulin) (C)
 Aldactone (Spironolactone) (C)
 Megace (Megestrol Acetate) (C)

Date: 02/28/05 **ISR Number:** 4592757-4 **Report Type:** Expedited (15-Day) **Company Report#:** US-SOLVAY-00204002739 **Age:** 18935 **DY Gender:** Male **I/FU:** F

<u>Outcome</u>	<u>PT</u>	<u>Report Source</u>	<u>Product</u>	<u>Role</u>	<u>Manufacturer</u>	<u>Route</u>	<u>Dose</u>	<u>Duration</u>
Death	Anaemia		Marinol	PS		ORAL	Daily Dose: unk.	
Hospitalization - Initial or Prolonged	Confusional State		Aranesp	SS		SUBCUTANEOUS	Daily Dose: 200 iu.	
	Convulsion		Oxycontin	SS		ORAL	Daily Dose: 40 mg.	31 DAY
	Face Injury		Aricept	SS		ORAL	Daily Dose: unk.	
	Fall		Neurontin	SS		ORAL	Daily Dose: unk.	
	Hepatic Neoplasm		Kytril	SS		INTRAVENOUS	Daily Dose: 1 mg.	1 DAY
	Malignant		Morphine Sulfate	C		UNKNOWN	Daily Dose: 15 mg.	
	Mental Status Changes						Frequency: As needed	55 DAY
	Nausea		Zoloft	C		ORAL	Daily Dose: 100 mg.	
	Pancytopenia		Procordia	C		ORAL	Daily Dose: 120 mg.	
	Vomiting		Dexamethasone	C		INTRAVENOUS	Daily Dose: 10 mg.	
							Frequency: Onc c	1 DAY
			Leukine	C		SUBCUTANEOUS	Daily Dose: 500 mg.	7 DAY
			Lasix	C		INTRAVENOUS	Daily Dose: 40 mg.	
							Frequency: Onc c	1 DAY
			Asa	C		ORAL	Daily Dose: 81 mg.	
			Dulcolax	C		RECTAL	Daily Dose: 5 mg.	
							Frequency: As needed	
			Pericolace	C		UNKNOWN	Daily Dose: 2 DF.	
			Pentamidine	C		RESPIRATORY (INHALATION)	Daily Dose: unk.	
			Levaquin	C		ORAL	Daily Dose: unk.	

**FDA - Adverse Event Reporting System (AERS)
Freedom Of Information (FOI) Report**

Ambien (Zolpidem Tartrate)	SS		
Senokot(Sennosidea+B)	SS		
Aldactone (Spirolactone)	SS		
Megacet (Megestrol Acetate)	SS		
Inderal (Propranolol Hydrochloride)	SS		
Magnesium	SS		400 MG
Acetylsalicylic Acid (Acetylsalicylic Acid)	SS		81 MG DAILY SEE IMAGE
Prograf (Tacrolimus)	SS		1 MG, INTRAVENOUS
Kytril (Granisetron)	C	INTRAVENOUS	
Chlorpromazine (Chlorpromazine)	C		
Glipizide (Glipizide)	C		
Procordia	C		
Pentamidine (Pentamidine)	C		
Peri-Colace (Sennodide A+B)	C		
Docusate Sodium	C		
Dulcolax	C		
Dexamethasone (Dexamethasone)	C		
Cis-Platinum (Cisplatin)	C		
Zoloft (Sertraline Hydrochloride)	C		
Leukine	C		
(Sargramostim)	C		
Adriamycin (Doxorubicin)	C		

Date: 03/08/05 ISR Number: 4604328-1 Report Type: Expedited (15-Day) Company Report#: 2005035080 Gender: Male Age: I/FU: 1

<u>Outcome</u>	<u>PT</u>	<u>Report Source</u>	<u>Product</u>	<u>Role</u>	<u>Manufacturer</u>	<u>Route</u>	<u>Dose</u>	<u>Duration</u>
Hospitalization - Initial or Prolonged	Anal Fissure Constipation Haemorrhoids Rectal Haemorrhage	Literature Health Professional	Camptosar (Irinotecan Hydrochloride)	PS		INTRAVENOUS	16 MG (CYCLIC), INTRAVENOUS	
			Methadone Hydrochloride (Methadone Hydrochloride)	SS		ORAL	7.5 MG (3 IN 1 D), ORAL	
			Temozolomide (Temozolomide)	SS		ORAL	160 MG (CYCLIC), ORAL	
			Dronabinol (Dronabinol)	SS		ORAL	5 MG (2 IN 1	

**FDA - Adverse Event Reporting System (AERS)
Freedom Of Information (FOI) Report**

D), ORAL

Gabapentin (Gabapentin)
Modafinil (Modafinil)

C

C

Date: 04/18/05 ISR Number: 4639296-X Report Type: Expedited (15-Day) Company Report#: USA-2004-0016457

Age: 51 YR Gender: Male IFU: F

Outcome	PT	Report Source	Product	Role	Manufacturer	Route	Dose	Duration
Hospitalization - Initial or Prolonged	Asthma	Health	Oxycontin Tablets	PS			20 MG, Q12H	
	Blood Glucose Increased	Professional	(Oxycodone Hydrochloride) Cr					
	Blood Magnesium Decreased	Other	Tablet					
	Blood Sodium Decreased		Oxyir Capsules 5 Mg					
	Brain Oedema		(Oxycodone Hydrochloride,					
	Confusional State		Oxycodone Hydrochloride)	SS			5 MG, Q4H	
	Contusion		Aranesp					
	Fall		(Darbepoetin)	SS				
	Fatigue		Kytril (Granisetron)	SS				
	Injury		Prograf (Tacrolimus)	SS		INTRAVENOUS	1 MG, INTRAVENOUS SEE IMAGE	
	Mental Status Changes		Protonix	SS			40 MG, DAILY	
	Nausea		(Pantoprazole)					
	Pancytopenia		Acetylsalicylic Acid	SS				
	Reticulocyte Count Increased		(Acetylsalicylic Acid)	SS			81 MG, DAILY	
	Vomiting		Gabapentin	SS				
			(Gabapentin)					
			Magnesium	SS				
			(Magnesium)					
			Donepezil	SS				
			(Donepezil)					
			Inderal	SS				
			(Propranolol Hydrochloride)					
			Dronabinol	SS				
			(Dronabinol)					
			Megace (Megestrol Acetate)	SS				
			Insulin (Insulin)	SS				
			Aldactone	SS				
			(Spirolactone)					
			Ambien (Zolpidem Tartrate)	SS				
			Senokot (Sennoside A+B)	C				
			Chlorpromazine (Chlorpromazine)	C				
			Glipizide	C				
			(Glipizide)					
			Procordia	C				
			Pentamidine (Pentamidine)	C				
			Peri-Colace (Sennoside A+B,					
			Docusate Sodium) Tablet	C				
			Dulcolax	C				

**FDA - Adverse Event Reporting System (AERS)
Freedom Of Information (FOI) Report**

Dexamethasone
(Dexamethasone) C
Cis-Platinum C
(Cisplatin)
Zolof (Sertraline) C
Hydrochloride
Leukine C
(Sargramostim)
Adriamycin C
(Doxorubicin)

Date: 05/23/05 **ISR Number:** 4673229-5 **Report Type:** Direct **Company Report#:** CTU 249270 **Age:** 66 YR **Gender:** Male **I/FU:** 1

Outcome: Disability
PT: Agitation
Diarrhoea
Hypertension
Mydriasis
Serotonin Syndrome
Tremor

Report Source:
Product: Zyxov
Role: PS
Manufacturer:
Dose: 600 MG IV Q
12 H
25 QD
25 DC BID

Route: INTRAVENOUS
Duration:

Date: 06/06/05 **ISR Number:** 4682446-X **Report Type:** Expedited (15-Day) **Company Report#:** US-ROCHE-380104 **Age:** 51 YR **Gender:** Male **I/FU:** F

Outcome: Hospitalization - Initial or Prolonged
PT: Anaemia
Convulsion
Disease Progression
Gastrointestinal
Haemorrhage
Haemolytic Anaemia
Liver Transplant
Rejection
Mental Status Changes
Metabolic Encephalopathy
Nausea
Pancytopenia
Vomiting

Report Source:
Product: Granisetron
Hydrochloride
Darbepoetin Alfa
Dronabinol
Oxycodone
Gabapentin
Donepezil
Hydrochloride
Zolpidem Tartrate
Morphine Sulfate
Chlorpromazine
Oxyir
Tacrolimus
Pantoprazole
Prandin
Sertraline
Hydrochloride
Glipizide
Nifedipine
Magnesium
Levofloxacin
Pentamidine
Pericolace
Bisacodyl
Frusemide
Acetylsalicylic Acid
Sargamostim
Dexamethasone
Doxorubicin
Cisplatin
Senna Fruit
Propranolol
Multivitamins

Route: INTRAVENOUS
SUBCUTANEOUS
UNKNOWN
UNKNOWN
UNKNOWN
UNKNOWN
Duration: 1 DAY
87 DAY
31 DAY
55 DAY

**FDA - Adverse Event Reporting System (AERS)
Freedom Of Information (FOI) Report**

Insulin C
 Spironolactone C
 Megestrol Acetate C

Date: 06/20/05 **ISR Number:** 4694272-6 **Report Type:** Expedited (15-Day) **Company Report#:** US-SOLVAY-00205001930 **Age:** 758 MON **Gender:** Female **I/FU:** 1

Outcome
 Hospitalization -
 Initial or Prolonged

PT
 Drug Ineffective
 Intestinal Obstruction

Report Source

Product
 Marinol

Manufacturer

Role
 PS

Route
 ORAL

Duration

Dose
 Daily dose: 5
 milligram(s)
 5 DAYS
 WEEK/EVERY 3
 WEEKS

Product
 Topotecan

C

INTRAVENOUS

Dose
 Daily dose:
 unknown

Duration

Dose
 Daily dose:
 unknown

Product
 Synthroid

C

ORAL

Dose
 Daily dose:
 unknown

Duration

Dose
 Daily dose:
 unknown

Product
 Zelnorm

C

ORAL

Dose
 Daily dose:
 unknown

Duration

Dose
 Daily dose:
 unknown

Product
 Reglan

C

ORAL

Dose
 Daily dose:
 unknown

Duration

Dose
 Daily dose:
 unknown

Product
 Coumadin

C

ORAL

Dose
 Daily dose:
 unknown

Duration

Dose
 Daily dose:
 unknown

Product
 Wellbutrin

C

ORAL

Dose
 Daily dose:
 unknown

Duration

Dose
 Daily dose:
 unknown

Product
 Ativan

C

ORAL

Dose
 Daily dose:
 unknown

Duration

Dose
 Daily dose:
 unknown

Product
 Zofran

C

ORAL

Dose
 Daily dose:
 unknown

Duration

Dose
 Daily dose:
 unknown

Product
 Phenergan

C

UNKNOWN

Dose
 Daily dose:
 unknown

Duration

Dose
 Daily dose:
 unknown

Product
 Protonix

C

ORAL

Dose
 Daily dose:
 unknown

Duration

Dose
 Daily dose:
 unknown

Product
 Tpn

C

INTRAVENOUS

Dose
 Daily dose:
 unknown

Duration

Dose
 Daily dose:
 unknown

Date: 07/22/05 **ISR Number:** 4724979-3 **Report Type:** Direct **Company Report#:** CTU 254051

Outcome
 Hospitalization -
 Initial or Prolonged

PT
 Mental Status Changes

Report Source

Product
 Dronabinol

Role
 PS

Manufacturer

Route

Dose

Duration

Dose
 Daily dose:
 unknown

Summary report for FOI selections:

Selection by inexact search of active ingredient: DRONABINOL %

Selection by inexact search of Tradename/Verbatim: MARINOL %

Total number of reports: 102

From: 01-NOV-1997 To: Present